Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 6, 2026CancersOpen Access

Actionable Genomic Alterations and Survival in Gallbladder Cancer: A Documented Stage- and Treatment-Matched Real-World Global Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZSZeeshan SolangiKZKatherin Zambrano-VeraLHLaura Haas

Discussion

Loading...

Member takes

Overview

Real-world analysis shows documented genomic alterations worsen mortality in gallbladder cancer, indicating disparities in genomic access.

Key Points

  • To evaluate the association of actionable genomic alterations with survival in gallbladder cancer, accounting for clinical confounders.
  • Utilized TriNetX Global Collaborative Network to identify adults with gallbladder cancer.
  • Created two propensity score-matched models based on demographic and clinical factors.
  • Conducted risk analysis and Kaplan–Meier survival methods to evaluate outcomes.
  • Documented AGA cohort exhibited higher mortality rates (52.8% vs. 42.5%) and shorter median OS (684 vs. 948 days).
  • In primary analysis, mortality was still higher in the documented AGA cohort (56.2% vs. 43.0%).
  • KRAS alterations indicated worse survival outcomes, whereas TP53 results were limited by small samples.

Cite This Study

Solangi et al. (2026) studied this question.

synapsesocial.com/papers/69faa22704f884e66b532bb0https://doi.org/10.3390/cancers18091452
View Full Paper
Ask AI
Bookmark
Share